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Letters to the Editor 
Dear Editor 
Optimizing nebulization practice 
We read with interest the short report by Caldwell 
and Milroy (1). They present the problems faced by 
their unit in setting up and running nebulizer guide- 
lines in hospital practice. This problem is not new, 
and has been similarly faced by other centres trying 
to achieve standardization and optimization of 
nebulizer practice in wards within large hospitals. 
We would, however, like to express our concern 
regarding certain aspects of their proposals. 
A 4-ml fill volume has been recommended. The 
authors do not state the type of nebulizer chamber 
with which it is appropriate to use this volume. In 
1983, Pavia et al. made a recommendation to use a fill 
volume of 4.0 ml (2). This was for use with a Hudson 
nebulizer chamber with a residual volume of 1.0 ml. 
These particular chambers are no longer available 
and the newer models have smaller residual volumes. 
Recent work has demonstrated that there is little 
advantage in giving larger fill volumes when the 
residual volume is small (i.e. around 0.5 ml), since the 
same amount of drug is delivered to the patient, but 
in a shorter period of time, resulting in a probable 
improvement in compliance with treatment (3). By 
using 2.0-2.5 ml of drug supplied in ampoules by the 
manufacturers, there is no need to add diluent, thus 
reducing the additional costs of needles, syringes and 
diluent itself, and furthermore reducing the possibil- 
ity of needle-stick injuries to staff and patients. 
The choice of flow rate is debatable, and it is 
unclear whether the authors are referring to the flow 
at the nebulizer or at the flow generator. It is 
important that a flow rate of 6-X 1 min - ’ is achieved 
at the nebulizer. Even so, depending on the nebulizer 
chamber used, a significant variation in particle size 
distribution can occur. Therefore, the blanket state- 
ment that at least 65% of the droplets are below 5 pm 
may be incorrect, unless the nebulizer chamber and 
its flow rate at the nebulizer is known. Finally, the 
authors make no statement about the use of mouth- 
pieces for the nebulization of ipratropium bromide 
and steroids, which is important to prevent possible 
eye or skin irritation occurring. 
A. H. HENDRICK AND E. C. SMITH 
Bristol Royal Injirmary, U.K. 
15 February 1995 
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Reply to Drs Kendrick and Smith 
Reading the comments, I agree that in the real world 
a fill volume of 2.5 ml is entirely reasonable. I also 
think the other comments made by Drs Kendrick and 
Smith are correct and helpful, and thank them for 
their contribution to what continues to be an area of 
debate in many hospitals. 
R. MILROY 
Stobhill NHS Trust, 
Glasgow, U. K. 
15 September 1995 
Dear Editor 
Optimizing nebulization practice 
I am writing in response to a short report by 
Caldwell and Milroy (1). The report was entitled 
‘Optimizing nebulization practice within a large 
teaching hospital: easier said than done’ which 
looked at the impact of issuing guidelines for nebuli- 
zation on the many variables involved. I noted with 
interest that the authors thought that the results were 
disappointing despite the guidelines to one patient 
group being re-inforced by pharmacist tutorial. 
I would like to comment on Caldwell and Milroy’s 
choice of recommending 4 ml as the final volume in 
Point 5 of their guidelines which they state was for 
reasons of ‘balancing residual volume with time to 
nebulize’. 
There are three main parameters to consider when 
nebulizing drugs to patients: 
(1) Quantity of aerosol, i.e. total output per 
treatment; 
(2) Quality of aerosol, i.e. percentage of aerosol in 
the respirable range; and 
(3) Time taken to complete treatment. 
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QUANTITY OF AEROSOL 
The importance of the effect of residual volume on 
quantity of aerosol can be illustrated in the following 
example: 
Nebulizer A 
Fill volume 2 ml, Residual volume 1 ml 
Total output =50% 
Nebulizer A 
Fill volume 4 ml, Residual volume 1 ml 
Total output =75% 
It can be seen that only half of the initial volume is 
nebulized with a 2 ml fill volume and there is a 
significant (50%) increase in total output when we 
move from 2 to 4 ml. 
If we now consider the same two cases with 
Nebulizer B, having a residual volume of 0.5 ml, it 
can be seen that the increase in the total output is less 
significant when we move from 2 to 4 ml. More 
importantly, however, is the fact that Nebulizer B 
with a 2 ml fill volume gives the same total output as 
Nebulizer A with a 4 ml fill volume. 
Nebulizer B 
Fill volume 2 ml, Residual volume 1.5 ml 
Total output =75% 
Nebulizer B 
Fill volume 4 ml, Residual volume 0.5 ml 
Total output =87.5% 
In practice, if the residual volume of a nebulizer is 
inherently high, then it is common to add saline to 
the initial fill volume in an effort to increase total 
output. 
QUALITY OF AEROSOL 
The quality of the aerosol produced by a nebulizer 
is extremely important as this determines how much 
of the aerosol can penetrate the lungs and thus 
deposit drug to the targeted site. In practice, if the 
percentage of output in the respirable range is inher- 
ently low for a particular nebulizer, the only option 
left to increase the quantity of drug depositing in the 
lung is to increase the fill volume. 
TIME TAKEN TO COMPLETE TREATMENT 
Diluting the initial fill volume with saline substan- 
tially increases the treatment time (2). This increase in 
fill volume may have a detrimental effect on the 
prescribed treatment as longer treatment times result 
in poor compliance due to the patient becoming 
irritated, bored or uncomfortable. 
It is often the case that the higher quantity and 
increased quality of aerosol mean longer treatment 
times. However, by designing nebulizers that work 
efficiently and have low residual volumes, it is poss- 
ible to reduce nebulization time at no cost to quantity 
or quality of aerosol produced. One such nebulizer is 
the Sidestream@. In a recent research paper compar- 
ing 17 commercial jet nebulizers, the total output ‘TO 
of Sidestream was significantly greater than all the 
others’ (3), the percentage of output in the respirable 
range (l-5 ,um) ‘PORR of Sidestream was signifi- 
cantly greater than all others’, and the treatment time 
for a 2.5-ml fill volume was 7.14 min. 
The point is highlighted further in a paper which 
looked at how the output of four drugs varied with 
fill volume. The authors state that ‘overall the Side- 
stream offered the best performance for each drug, 
consistently releasing relatively large fractions of the 
initial mass of each of the drugs in aerosol form in 
relatively short times’ (4). Furthermore, in two of the 
four drugs used ‘the percentage of drug released by 
the Sidestream varied by only 15% over the range 2 
to 6 ml .’ (4). 
In conclusion, I would like to quote from a 
research paper produced by Queen’s Medical Centre, 
Nottingham in which the final two sentences state ‘In 
the meantime, the acceptability of this form of treat- 
ment (nebulization) would be improved by attempt- 
ing to shorten rather than extend treatment times (5). 
The most effective way would be to use more concen- 
trated solutions, use smaller fill volumes, and design 
nebulizers with smaller ‘dead volumes’ rather than 
rely on measures such as diluting solution and 
tapping the nebulizer chamber’ (6). 
H. BURNETT 
Medic-Aid Limited, 
Pagham, West Sussex, U.K. 
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